Adaptimmune, which focuses on the use of T-cell therapy to treat cancer and infectious diseases, has completed a huge series A round to expand its clinical trials.
UK-based biotechnology company Adaptimmune has secured $104m in a series A round featuring Denmark-based pharmaceutical company Novo.
The round was led by venture capital firm New Enterprise Associates, with involvement from Fidelity Biosciences, which invests as a subsidiary of fund manager Fidelity Investments, investment firms OrbiMed Advisors and Wellington Management Company, and VC firms Foresite Capital Management, Ridgeback Capital Management, QVT, Rock Springs Capital, VenBio Select and Merlin Nexus.
Adaptimmune specialises in T-cell receptor technology, which it is developing…
